Acute Porphyria Drug Database

J07BD52 - Measles, Combinations with Mumps and Rubella, Live Attenuated
Propably not porphyrinogenic
PNP

Important Information
In general, vaccines are regarded safe since such substance is not suspected to give an up-regulation of the heme biosynthesis as a direct effect. However, some vaccines can cause a reaction with high fever persisting over days as a side effect. It is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to. Vigilance is therefore motivated when administrating a vaccine known to cause reactions with fever.
Side effects
Fever is reported as a very common side effect the combined measles, mumps and rubella vaccine, and it is possible that this side effect can trigger an acute porphyric attack in the same way as infections are known to.
Rationale
Based on the pharmacokinetics of the measles, combinations with mumps and rubella vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Live, attenuated measles, mumps and rubella viruses.
Therapeutic characteristics
The measles, combinations with mumps and rubella vaccine is indicated for simultaneous vaccination against measles, mumps, and rubella in individuals from 12 months of age. It is administered by intramuscular injection.
Metabolism and pharmakokinetics
The measles, combinations with mumps and rubella vaccine is not metabolized by the Cytochrome P450 system.

References

  1. Government bodies
  2. Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015). #1857
  3. Summary of Product Characteristics
  4. The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). M-M-RVAXPRO. (Last edition: 20.11. 2014). #1878

Similar drugs
Explore alternative drugs in similar therapeutic classes J07B / J07BD or go back.

 
© NAPOS 2024
An unhandled error has occurred. Reload 🗙